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Abstract
Human artificial chromosomes (HACs), which carry a fully functional centromere and are maintained as
a single-copy episome, are not associated with random mutagenesis and offer greater control over
expression of ectopic genes on the HAC. Recently, we generated a HAC with a conditional centromere,
which includes the tetracycline operator (tet-O) sequence embedded in the alphoid DNA array. This con-
ditional centromere can be inactivated, loss of the alphoidtet-O (tet-O HAC) by expression of tet-repressor
fusion proteins. In this report, we describe adaptation of the tet-O HAC vector for gene delivery and gene
expression in human cells. A loxP cassette was inserted into the tet-O HAC by homologous recombination
in chicken DT40 cells following a microcell-mediated chromosome transfer (MMCT). The tet-O HAC with
the loxP cassette was then transferred into Chinese hamster ovary cells, and EGFP transgene was efficiently
and accurately incorporated into the tet-O HAC vector. The EGFP transgene was stably expressed in human
cells after transfer via MMCT. Because the transgenes inserted on the tet-O HAC can be eliminated from
cells by HAC loss due to centromere inactivation, this HAC vector system provides important novel fea-
tures and has potential applications for gene expression studies and gene therapy.
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1. Introduction
Human artificial chromosomes (HACs) are an impor-
tant alternative to conventional gene-transfer tech-
niques, such as viral, plasmid, P1 phage-derived
artificial chromosomes, bacterial artificial chromo-
somes (BACs) and yeast artificial chromosomes,
because they offer greater control over their location
and function in recipient human cells. Advantages of
HAC vectors include their stability as episomes in
human cells, a low level of associated insertional muta-
genesis, a low potential for causing cell transformation
compared with the conventional vectors1,2 and
capacity to carry and facilitate expression of the
largest mammalian genes from their native gene regu-
latory elements.
Two strategies have been used to construct HAC
vectors3,4: natural human chromosomes have been
modified and reduced in size to generate minichro-
mosomes that maintain the essential functional
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properties of a eukaryotic chromosome and cloning
vector (top-down), or de novo artificial chromosomes
have been constructed from synthetic or cloned
DNA that provide such essential functions (i.e.
alphoid DNA for kinetochore function) in human
and other mammalian cells (bottom-up). Top-down
HACs have been generated from human chromo-
somes by telomere-seeding and homologous recom-
bination in chicken DT40 cells.5,6 For example, our
group recently constructed a human chromosome
14- and 21-derived HAC vector that replicates and
segregates properly during mitotic divisions in vitro
and is stably maintained in mice.4–8 The chromo-
some 21-derived HAC is a powerful gene delivery
vector capable of carrying large genes such as the dys-
trophin gene (2.4 Mb) and may be useful for gene
and cell therapy.4,9–11
Bottom-up HACs have been constructed from arrays
of synthetic or natural alphoid DNA and BAC vector
sequences required for HAC assembly and propa-
gation.12–14 Recently, our group constructed a
bottom-up HAC in which 6000 copies of a 42-bp
tetracycline operator (tet-O) sequence are inserted
into a mega-base size synthetic alphoid DNA array.
Because tet-O is bound with very high affinity and
specificity by the tet repressor (tet-R), the tet-O
sequences in the HAC can be targeted with tet-R
fusion proteins that inactivate the centromere and
induce HAC loss. Thus, the alphoidtet-O HAC hereafter,
tet-O HAC has a conditional centromere, that can be
turned on or off by co-expression of tet-O binding
proteins. This feature of the tet-O HAC was used to
target chromatin-modifying proteins into the HAC
centromere and alter the balance between open
and condensed chromatin, which is critical for the
kinetochore function.15,16 In this study, we describe
adaptation of the tet-O HAC for gene expression
studies.
2. Materials and methods
2.1. Cell culture
HT1080 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Sigma, St Louis, MD, USA)
supplemented with 10% fetal bovine serum (FBS;
Biowest, Nuaille, France) with 4 mg/ml of Blasticidin
S (BS; Funakoshi, Tokyo, Japan) at 378C in 5% CO2.
The HT1080 and A9 hybrid cells were maintained
in DMEM (Sigma) containing 10% FBS (Biowest)
and the appropriate antibiotics. The hypoxanthine
phosphoribosyltransferase (HPRT)-deficient Chinese
hamster ovary (CHO) cells (JCRB0218) were main-
tained in Ham’s F-12 nutrient mixture (Invitrogen,
USA) plus 10% FBS with 8 mg/ml of BS (Funakoshi).
After introduction of the EGFP gene, the CHO cells
retaining the tet-O-EGFP HAC were cultured with
1 HAT medium. Chicken DT40 cells were main-
tained at 378C in RPMI 1640 medium supplemented
with 10% FBS, 1% chicken serum and 50 mM 2-
mercaptoethanol.
2.2. Construction of the targeting vectors
The targeting vector 5–4–3 for introducing a 30-
HPRT-loxP-Hyg-thymidine kinase (Tk) cassette was
constructed as follows. The 2.0- and 3.1-kb fragment
homologous for BAC vector sequences in the tet-O
HAC were amplified by PCR using primers HR1-Fi/Ri
50-AGAGTTAACGTTACCTTCCACGAGCAAAACACGTA-30
and 50- AGAGTTAACCTTGTAGGCCTTTATCCATGCTGG
TT-30; HR3S-F/R 50-ATACCGCGGGTTCTGTGTTCATTA
GGTTGTTCTGT-30 and 50-ATACCGCGGTGAAGCGTA
TATAGGACGAGTAACTG-30, digested with either HpaI
or SacII and subcloned into the equivalent sites of
pKO Scrambler V901 backbone vector (Lexicon
Genetics, Woodlands, TX, USA), respectively, which
contains the following three selection/insertion cas-
settes between the EcoRI and the BglII sites: a 2-kb
fragment from pMC1-Tk (Stratagene, La Jolla, CA,
USA) containing the HSV-Tk gene, a 2.3-kb XbaI/AscI
fragment from pKO SelectHPRT V820 (Lexicon
Genetics) containing a part of the human HPRT
gene with the loxP site inserted into the XbaI site of
intron B and a 1.3-kb XhoI fragment from the PGK/
Hyg vector containing the hygromycin-resistance
gene. The transgene sequences are described
previously.7
2.3. Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) analyses of
CHO and DT40 cells were performed with either fixed
metaphase or interphase nuclei using digoxigenin-
labelled (Roche, Basel, Switzerland) human hCot1
DNA (Invitrogen) and biotin-labelled plasmid DNA,
as described previously.7 For FISH analysis of HAC in
HT1080 cells, tet-O alpha-satellite DNA was used as
a probe.15 Chromosomal DNA was counterstained
with DAPI (Sigma). The images were captured using
the Argus system (Hamamatsu Photonics,
Hamamatsu, Japan) and NIS elements (Nikon, Tokyo,
Japan).
2.4. Microcell-mediated chromosome transfer
Microcell-mediated chromosome transfer (MMCT)
was performed as described previously.7,10 The tet-O
HAC containing the loxP cassette was transferred
from DT40 into CHO cells by MMCT technology.
Briefly, microcells were prepared by centrifugation of
1  109 DT40 cells attached on flasks (Nalge Nunc,
Rochester, NY, USA) coated with poly-L-lysine
(Sigma) and were fused to 1  106 CHO cells by
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47% polyethylene glycol 1000 (WAKO, Osaka, Japan).
CHO hybrids were selected in the presence of 4 mg/ml
of BS and collected for expansion. After construction
of the tet-O-EGFP HAC vector by Cre/loxP recombina-
tion in CHO cells, the HAC was transferred from CHO
into HT1080 cells via MMCT. The HT1080 hybrids
were selected in the presence of 4 mg/ml of BS.
2.5. PCR analyses
Genomic DNA from cell lines was extracted using a
genomic extraction kit (Gentra System, Minneapolis,
MN, USA). PCR analyses were carried out using stan-
dard techniques. The primer pairs for detection of
the HAC were: BACpr-F/BACpr-R (4075 bp), 50-CTCT
ATACACTCAGTTGGAACACGAGAC-30 and 50- GAGCCT
GTGTAGCGTTTATAGGAAGTAG-30. The primer pairs
for confirmation of targeting of the loxP cassette
into the HAC were: HRL-F/TKpAF (4.1 kb), 50-CAGAG
CCAGACAGGAAGGAATAATGTCAAG-30 and 50-CCGG
ACGAACTAAACCTGAC-30; PGKr-3/HRR-R (3.5 kb), 50-
CCAGAGGCCACTTGTGTA-30 and 50-GCATCTCAATTAG
TCAGCAACCATAGTCCC-30. The primer pairs for detec-
tion of the HPRT gene reconstruction were: Trans-L1/
R1 (409 bp), 50-TGGAGGCCATAAACAAGAAGAC-30
and 50-CCCCTTGACCCAGAAATTCCA-30. The primer
pairs for determination of the EGFP gene were:
EGFPL/R (479 bp), 50-CCTGAAGTTCATCTGCACCA-30
and 50-TGCTCAGGTAGTGGTTGTCG-30. Primers
FurinF/R, 50-ACTCAGAGATCCACTGCACCAGGATCCAA
GGGAGG-30 and 50-CCGCTCGAGCGGCTACACCACAG
ACACCATTGTTGGCTACTGCTGCC-30, were used as an
internal control for CHO cells after HAC transfer into
human cells via MMCT.
2.6. HAC elimination by its targeting with chromatin
modifiers
HT1080 cells expressing the tTS fusion proteins
were obtained using a retroviral vector as described
previously.15 A retroviral expression vector was
transfected into 293FT cells (Invitrogen) with
Lipofectamine2000 (Invitrogen). After 4 h, the
medium was changed with a fresh medium. After
48 h, the supernatant was collected by centrifugation
at 1500 rpm and an aliquot (2–5 ml) was added to
HT1080 cells carrying the HAC. The infected cells
were cultured with 800 mg/ml of geneticin and
1 mg/ml of doxycycline (dox) for 24 h. After 7 days
of culture in the presence of geneticin, an elimination
assay was performed under the culture conditions:
dox(2) 7 days, dox(þ) 7 days and dox(þ) 7 days
ganciclovir(þ) 5 days.
2.7. FACS analysis
Mitotic stability of the HAC carrying the EGFP gene
was determined by FACS as described previously.17
2.8. Southern blot analysis
Southern blot hybridization was performed as
described previously with a 32P-labelled probe.18
Genomic DNA from cells containing the tet-O HAC
was digested by SpeI, CHEF separated, and blot-hybri-
dized with a 201-bp probe specific to a sequence cor-
responding to the BAC vector region that is repeated
47 times in the HAC. The probe was amplified by
PCR using the following 4243/4443 primers 50-
GGGCAATTTGTCACAGGG-30 and 50-ATCCACTTATCCA
CGGGGAT-30. Blots were incubated for 2 h at 658C
in pre-hybridization solution (0.5 M Na-phosphate
buffer containing 7% SDS and 100 mg/ml of
unlabelled salmon sperm carrier DNA). Labelled
probe (20 ml) was heat denatured in boiling water
for 5 min and snap cooled on ice. The probe was
added to the hybridization buffer and allowed to
hybridize overnight at 658C. Blots were washed
twice in 2 SSC (300 mM NaCl, 30 mM sodium
citrate, pH 7.0), 0.1% SDS for 30 min at room temp-
erature, then three times in 0.1 SSC, 0.1% SDS for
30 min at 658C. Blots were exposed to X-ray film for
24–72 h at 2708C.
3. Results and discussion
3.1. Retrofitting the tet-O HAC with a loxP cassette in
DT40 cells
The tet-O HAC was constructed in human fibrosar-
coma HT1080 cells,15 because these are the only cells
that support efficient formation of HACs from alphoid
DNA arrays. Subsequently, the tet-O HAC was trans-
ferred into chicken DT40 cells, the standard host for
homologous targeting of HACs and mammalian
chromosomes by homologous recombination. In
addition, DT40 cells form microcells, which facilitate
transfer of modified HACs to other mammalian cells.
The overall strategy used to modify the tet-O HAC is
shown in Fig. 1. First, HT1080 cells carrying the tet-
O HAC were fused to high-microcell forming mouse
A9 cells, and hybrid A9BH-3 cells were isolated
under selection for resistance to BS and G418. The
morphology of A9BH-3 cells was similar to that of
A9 cells (Fig. 2A), but different from the morphology
of HT1080 cells. HAC-specific PCR and FISH was
used to confirm the presence of the tet-O HAC in
A9BH-3 hybrid cells (Fig. 2B). The hybrid cells form
microcells in response to colcemid treatment (data
not shown). Second, the tet-O HAC was transferred
from hybrid cells into chicken DT40 cells by MMCT.7
In DT40 cells, the tet-O HAC was maintained autono-
mously without integration into chromosomes
(Fig. 2C). The loxP-targeting cassette containing the
drug-resistance marker hygromycin, the 50-end of
the HPRT gene, and the Tk gene was introduced into
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the tet-O HAC by homologous recombination in
DT40 cells as shown in Fig. 2D. More than 30 clones
were obtained under selection for hygromycin. FISH
analysis showed that the loxP cassette recombined
into the HAC but not into host chromosomes, and
the modified HAC remained stable as an episome
(Fig. 2E and Supplementary Table S1) with no detect-
able change in HAC structure, as detected by Southern
blot hybridization. These data show that MMCT suc-
cessfully transferred the HAC to recipient DT40 cells
and that HAC modification by homologous recombi-
nation proceeded with high fidelity (Supplementary
Fig. S1).
The tet-O HAC carries 47 copies of the BAC vector
used for assembly and propagation of synthetic alphoid
DNA arrays.15 The loxP cassette shares homology with
the BAC sequences on the tet-O HAC and is targeted
into these sequences at one or more sites by homolo-
gous recombination in DT40 cells. The copy number of
the loxP cassette in the tet-O HAC was 1–32, as deter-
mined by a real-time PCR (Supplementary Fig. S2). Two
clones, DT40/BHI 1–38 and DT40/BHI 2–2, with 1
and 20 copies of the loxP cassette, respectively,
were chosen for further analysis.
To investigate whether the tet-O HAC with the loxP
cassette retained a conditional centromere, a tet-R-
transcriptional transactivator fusion protein was
expressed in DT40 cells using the pTet-on advanced
vector (TAKARA). The pTet-on expression construct
containing the reverse transcriptional transactivator
(rtTA) and the Neo gene was introduced by electro-
poration into DT40/BHI 1–38 and DT40/BHI 2–2
cells, and HAC retention was measured by FISH analy-
sis. Using this ‘tet-on’ expression system, the rtTA
fusion binds to tet-O sequences in the presence of
doxycycline, causing centromere inactivation and
HAC destabilization. HAC retention was measured by
FISH analysis in two randomly selected DT40/BHI
1–38 and DT40/BHI 2–2 cultures maintained for 7
days in the presence or the absence of doxycycline
(when the rtTA fusion protein does not bind to the
centromere; Supplementary Fig. S3). The results indi-
cated that retention of the tet-O HAC decreased dra-
matically when DT40 cells were grown in the
presence of doxycycline. Thus, the tet-O HAC retains
a conditional centromere after MMCT into DT40
cells and insertion of the loxP cassette by targeted
recombination.
Figure 1. Schematic diagram of construction of the tet-O HAC-based vector for regulated expression of genes. (A) The tet-O HAC was
constructed in human HT1080 cells. HT1080 carrying the tet-O HAC and mouse A9 cells were fused. (B) Hybrid cells carrying the
tet-O HAC were transferred into chicken DT40 cells by MMCT. (C) The loxP/HPRT cassette was inserted into the tet-O HAC by
homologous recombination in DT40 cells. (D) The tet-O HAC vector was transferred into CHO cells deficient in HPRT. (E) The EGFP/
HPRT cassette was introduced into the HAC by Cre/loxP recombination in CHO cells. (F) The tet-O-EGFP HAC was transferred into
human HT1080 cells by MMCT. The tet-O HAC was destabilized by expression of a chromatin modifier gene fused with tet-R.
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3.2. EGFP transgene insertion into tet-O HAC by
Cre-loxP recombination in CHO cells
The tet-O HAC containing 1 and 20 copies of the
loxP site, BHI 1–38 and BHI 2–2 (Supplementary
Fig. S2), were transferred from DT40 cells to HPRT-
deficient CHO cells via MMCT. More than 20 BS-resist-
ant clones were obtained for each HAC. PCR analysis
with a set of HAC-specific primers that bind to a
region proximal to the loxP cassette showed that
roughly half of the BS-resistant clones maintained
the tet-O HAC (Supplementary Table S1). FISH analy-
sis showed that the tet-O HAC propagated autono-
mously (Fig. 3A and B). No detectable changes in
the HAC structure were detected by Southern blot
(Supplementary Fig. S1).
The loxP cassette in the modified tet-O HAC is
designed for site-specific gene targeting using Cre
recombinase. To test this feature and determine the
efficiency of gene targeting into the modified tet-O
HAC, an EGFP/HPRT transgene construct and a Cre-
recombinase expression vector were co-transfected
into CHO cells carrying the modified tet-O HAC with
1 and 20 copies of the loxP cassette (Fig. 3C and D).
Recombinant clones were selected by growth in HAT
medium for 12 days. PCR analysis with TRANS-L1/
TRANS-R1 primers showed that the HPRT gene was
reconstituted in all drug-resistant clones (Fig. 3F).
All the transfectants expressed the EGFP transgene. A
fluorescent image of one representative clone,
CHOBHIG-11, with the HAC that was transferred
from DT40/BHI 2–2 is shown in Fig. 3E. The efficiency
of targeting into both HACs was 2  1024, indicating
that the number of loxP cassettes in the HAC was not a
critical determinant of gene-targeting efficiency. The
same efficiency of HACs with 1-loxP copy and 20-loxP
copies might be explained by different accessibility of
loxP sites in the HAC with 20 copies, i.e. some loxP
sites may be ‘masked’ by heterochromatin. Expression
of the EGFP transgene was detected by fluorescence
microscopy and was stable for at least 12 weeks
under selective conditions (data not shown). The tet-
O-EGFP HAC also exhibited relatively high stability in
CHO cells (up to 50% HAC retention after 2 months
of growth under non-selective conditions). The tet-O-
EGFP HAC was inactivated and destabilized when rtTA
was expressed in these cells, as shown above in DT40
cells (Supplementary Fig. S3). Thus, the tet-O-EGFP
HAC retains a conditional centromere in CHO cells.
Figure 2. Insertion of the loxP cassette into the tet-O HAC by homologous recombination in DT40 cells. (A) Morphology of A9BH-3 hybrid
cells. (B) Genomic DNA from A9BH-3 hybrid cells was analysed by PCR using HAC-specific primers, HRL-F/R and BACpr-F/R. (C) FISH of
DT40/BH-1 cells using the hCot1 probe. The tet-O HAC is indicated by an arrowhead. (D) Insertion of the loxP/HPRT cassette into the
tet-O HAC using the targeting vector 5–4–3, which carries the regions of homology (black boxes) to BAC vector sequences in the HAC.
(E) FISH analysis of DT40/BHI 1–38 (left) and DT40/BHI 2–2 (right) cells. FISH analysis was performed using a biotin-labelled probe for
the loxP cassette (green) and digoxigenin-labelled human hCot1 (red).
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3.3. Propagation of the retrofitted tet-O HAC in human
HT1080 cells and expression of the reporter gene
The properties of the tet-O-EGFP HAC were re-
examined after transfer from CHOBHIG-11 into
human HT1080 cells via MMCT. Under selection for
BS, 15 drug-resistant clones that expressed the EGFP
transgene were isolated (Fig. 4A). PCR analyses with
a set of HAC-specific primers showed that all the 15
clones contain the HAC. FISH analysis showed
that the HAC was maintained autonomously in six
out of six randomly selected clones (Fig. 4B and
Supplementary Table S1).
The following experiments examine whether the
tet-O-EGFP HAC retains a conditional centromere
and determines the conditions that induce loss of
this HAC from HT1080 cells. In our previous study,15
we demonstrated that retro virus-induced tTS
expression is highly efficient in tet-O HAC elimination
in HT1080 cells but not efficient from the plasmid.
Therefore, a retroviral vector expressing tTS-EYFP was
introduced into HAC containing HT1080 cells as
described previously.15 This vector expresses a fusion
of tet-R and the Kruppel-associated box (KRAB)-AB
silencing a domain of the Kid-1 protein,19,20 which
binds to tet-O in the absence of doxycycline. After
transfection with the tTS fusion construct, neomy-
cin-resistant HT1080 clones were selected in the
presence of doxycycline, conditions that support
proper HAC segregation and HAC stability. The HAC
elimination assay was then performed by transfer of
the stable transfectants to media lacking doxycycline.
FISH analysis revealed dramatic HAC loss after removal
of doxycycline (Fig. 4E), which allows the tTS fusion
protein to bind to tet-O in the HAC centromere.
Thus, after three rounds of MMCT, the HAC retained
a conditional centromere. It is worth noting that no
detectable cell death was observed during inacti-
vation of kinetochore in the HAC, as reported
previously.15
The loxP cassette in the tet-O HAC also carries the
HSV-Tk gene, which can be selected against, because
it encodes a gene product that causes cell death in a
medium containing ganciclovir (Fig. 3C). Consistent
with this, FISH and FACS analyses showed that the
cells without HAC were selected when cells were
grown in the presence of ganciclovir (data not
shown). A fraction of tet-O HAC-less cells was even
higher when ganciclovir selection was combined
with tTS expression (Fig. 4E). Additional experiments
demonstrated that EGFP was stably expressed in
Figure 3. Insertion of the EGFP transgene into tet-O HAC in CHO cells. (A and B) FISH analysis of CHO metaphase spreads. FISH was
performed using a biotin-labelled probe for the loxP cassette (green) and digoxigenin-labelled human hCot1 (red). (C) Insertion of
the EGFP cassette into the tet-O HAC by Cre/loxP recombination. The pCMV-Cre expression vector and pCAG-EGFP 30-HPRT-loxP-
targeting vector were co-transfected into the CHO cells containing the tet-O HAC. (D) Map of the tet-O-EGFP HAC vector. (E) Bright
and fluorescent images of CHOBHIG-11 cells carrying the tet-O-EGFP HAC. (F) PCR analysis confirming a site-specific recombination
resulting in restoration of a functional HPRT. Primers TRANS-L1/TRANS-R1 were used to detect Cre/loxP recombination.
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HT1080 cells carrying the tet-O-EGFP HAC for at least
4 weeks (data not shown).
Together, these data show that the tet-O HAC with
a conditional centromere retains all its functional fea-
tures through three rounds of MMCT and two cycles
of targeted engineering. Furthermore, the engineered
features of the tet-O HAC and its derivatives, including
ability to stably express cloned transgenes, function
well in chicken DT40, hamster CHO and human
HT1080 cells. This suggests that the host cell environ-
ment does not significantly influence the functional-
ity of the tet-O HAC.
3.4. Potential of the tet-O HAC vector
In our previous studies, we developed the tet-O
HAC, whose centromere can be inactivated in
HT1080 cells by targeting with tet-R fusions with
eukaryotic chromatin modifiers.15,16 The tet-O HAC
is a unique system for the study of epigenetic modifi-
cations in the human kinetochore, but it cannot be
used for gene delivery and gene expression studies.
In this work, the tet-O HAC was further engineered
by insertion of a loxP-50 HPRT-Hyg-Tk cassette by
homologous recombination in chicken DT40 cells.
The modified HAC reported here has features that
allow it to be a useful vector for gene cloning, delivery
and expression in mammalian cells.
A transgene of 20 kb in size was efficiently
inserted into the loxP site in the modified tet-O HAC
by Cre-mediated recombination in CHO cells.
Insertion of human genes .60 kb in length was
recently also achieved (V.L., unpublished data).
Because CHO cells form microcells at a high fre-
quency, the HAC can be easily moved from donor
CHO cells into any recipient human or mouse cell
lines via MMCT for additional functional analysis.
Importantly, the centromere in the HAC can be
inactivated in all three animal cell types tested in
this study (human, hamster and chicken). This obser-
vation indicates that no significant primary sequence
or gross structural changes were introduced into the
HAC during three cycles of MMCT and that the func-
tionality of the conditional centromere is relatively
insensitive to host cell factors. Indeed, Southern blot
analysis of the tet-O HAC confirmed identical profiles
in all three host cells. In addition, an EGFP transgene
inserted into the loxP cassette could be stably
Figure 4. Analysis of the tet-O-EGFP HAC after its transferring into HT1080 cells. (A) The tet-O-EGFP HAC was hybridized with biotin-
labelled EGFP-targeting vector (green). (B) FISH analysis was performed on HT1080BHIG interphase nuclei as shown in (A). Two
hundred interphase nuclei were counted and a rate of the tet-O HAC retention was calculated (as described in the ‘Materials and
methods’ section) for six independent clones. (C) HT1080 cells were infected with a retroviral vector expressing the tet-R-tTS-EYFP
fusion. (D) Bright and fluorescent images of HT1080 cells. After infection, the cells were cultured under three conditions: dox(þ) 7
days, dox(2) 7 days and dox(2) 7 days plus GANC(þ) 5 days. Two hundred interphase nuclei were counted and a rate of the tet-O
HAC retention was calculated. (E) Tet-O HAC retention was calculated as described in (B).
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expressed for at least 12 weeks, despite the presence
of adjacent functional centromeric DNA. This suggests
that the functional kinetochore co-exists with perma-
nently open chromatin domains in mammalian cells.
However, additional studies are needed to determine
whether a transgene in the loxP cassettes on the tet-O
HAC requires specific insulator sequences, which
prevent gene silencing due to spreading of pericentro-
meric heterochromatin during cell propagation.
It is worth noting that this HAC cloning system is
compatible with the TAR cloning technology allowing
selective isolation of full-length genes from complex
genomes by homologous recombination in yeast.21
In particular, a newly developed TAR cloning vector
that contains the loxP/HPRT cassette can be used to
insert any TAR-isolated gene into the tet-O HAC with
a conditional centromere directly in CHO cells using
Cre/loxP recombination (V.L., unpublished data).
The tet-O HAC vector has significant advantages
over other expression/cloning systems, because it pro-
vides a mechanism to compare the phenotype of a
mammalian cell with or without a functional copy
of any cloned gene of interest. Thus, a rigorous nega-
tive control for phenotypic changes attributed to
expression of the cloned gene can be conducted
easily in any population of dividing cells by simply
inactivating the tet-O HAC centromere. Such controls
are required for proper interpretation of gene func-
tion studies. In addition, the modified tet-O HAC
vector can be used for experiments that require tran-
sient expression of a cloned gene of interest. For
example, iPS cells are generated by transient
expression of specific cellular factors, including
OCT4, SOX2, KLF4, cMYC and LIN28. In this case,
HAC elimination and removal of the stem cell-indu-
cing factors could provide a strategy to avoid inser-
tional mutagenesis and cell transformation,
complications that are frequently observed during
cell re-programming.22
The capacity for transient expression of cloned
genes is also important for other translational
research studies. For example, somatic mesenchymal
stem cells (MSCs) are mortal, so it is difficult to propa-
gate and expand MSC cultures for transplantation
experiments. This problem can be overcome by tran-
sient expression of human telomerase reverse tran-
scriptase (hTERT), which extends MSC life span by
preventing telomere shortening.23,24 However, our
study has shown that constitutive hTERT expression
in MSCs prevents their differentiation into muscle
cells, possibly because hTERT is normally down-regu-
lated during MSC differentiation (unpublished data).
Reversible immortalization by transient expression of
hTERT from a viral vector has already been reported
in human fibroblasts.25 However, even if the gene is
eliminated after transient expression from a viral
vector, use of the viral vector is associated with risk
of insertional mutagenesis leading to cancer or
other cellular dysfunction.2 So, complete elimination
of hTERT and vector sequences from MSCs after
reversible immortalization is preferred. The tet-O
HAC cloning system described in this work provides
an important tool for engineering differentiated cells
that can safely be used for cell transplantation.
In summary, the modified tet-O HAC described
here is a unique HAC-based cloning system for gene
expression and gene function studies. Because the
tet-O HAC is generated from synthetic alphoid DNA
arrays and vector DNA whose DNA sequence is com-
pletely defined, this mammalian cell cloning system
may have significant potential for gene therapy.
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